Invex Therapeutics Ltd (ASX:IXC)
Share Pricing & News Healthcare

AUD 0.565

0.015 (2.727%)
(As on 2022-11-29 20:56:26 AEDT)
Previous Close Open Close*
0.55 0.54 0.565
Market Cap Dividend Yield (Annualized)
AUD 42.462M 0.00%

Day Range
0.535L 0.565 H
52 WEEK HIGH LOW
0.435L 0.75 H

Chart Price & Information

Last Trade 0.565
Change% 2.7273
52 W H/L 0.750/0.435
EBITDA -4.242M
NPAT After Abnormal Items -3.953M
Equity 28.481M
ROE% -13.88%
Total Liabilities 1.004M
Total Revenue 182,251
Cash and Cash Equivalents 29.339M

Stock Information

Share price 0.565
Market Cap 42.462M
Price/Gross Cash Flow -13.18
Dividend Yield Excluding Special 0.00%
Ending Shares 75.154M
52-Week Range 0.750-0.435
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.38
P/E ratio 0.000
Sector P/E --
EPS -5.26
EV/EBITDA --
Net Profit Margin (%) --
Gross Cash Flows Per Share -0.04
Net Gearing -103.01%
Sales Per Share 0.00
Book Value Per Share 0.38

Similar Companies

Related Articles

About Company

Invex Therapeutics Ltd (ASX: IXC) a biopharmaceutical company, concentrates on developing effective treatments for neurological conditions, which is caused by raised intracranial pressure (ICP). ICP is considered as a serious issue in a range of neurological conditions, which includes idiopathic intracranial hypertension (IIH), traumatic brain injury or severe stroke. The company was established in March 2019 and is headquartered in Australia.

Corporate Information


Level 1, 38 Rowland Street, SUBIACO, WA, AUSTRALIA, 6008

Phone:+61 8 6382 0137

Website:http://www.invextherapeutics.com

Dividends

Ex-Date Net Dividend Frank Flag Period End Date Type Payable

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2023-08-18 2023
Report (Prelim) 2023-08-18 2023
Report (Interim) 2023-02-21 2023